[Skip to Content]
[Skip to Content Landing]
Comment & Response
March 2016

Neuraminidase Inhibitors and Influenza Infection

Author Affiliations
  • 1Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland
  • 2Centre for Evidence-Based Medicine, Oxford University, Oxford, United Kingdom

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(3):415-416. doi:10.1001/jamainternmed.2016.0016

To the Editor As authors of articles cited by Louis and Lampiris,1 we have a different view of the evidence that should inform recommendations about treating influenza with neuraminidase inhibitors.

Louis and Lampiris1 champion conclusions from observational studies. They judged the evidence from randomized clinical trials as inadequate because such trials have not been carried out in high-risk populations, which they defined as including children and the elderly. However, we analyzed 13 such placebo-controlled randomized clinical trials in our Cochrane review.2